Expression of vascular endothelial growth factor in malignant mesothelioma

Anticancer Research

Volumn 26, Issue 6 C, 2006, Pages 4833-4836

  Aoe, Keisuke ^a   Hiraki, Akio ^a   Tanaka, Takehiro ^b   Gemba, Ken Ichi ^b   Taguchi, Koji ^d   Murakami, Tomoyuki ^a   Sueoka, Naoko ^c   Kamei, Toshiaki ^e   Ueoka, Hiroshi ^a   Sugi, Kazuro ^a   Yoshino, Tadashi ^b   Kishimoto, Takumi ^d  

^a NATIONAL SANYO HOSPITAL   (Japan)

^b OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c SAGA UNIVERSITY   (Japan)

^d OKAYAMA ROSAI HOSPITAL   (Japan)

^e Yamaguchi Grand Medical Center   (Japan)

Author keywords

Immune escape mechanism; Malignant mesothelioma; Prognostic factor; VEGF

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIOID CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33845924511     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Robinson BWS and Lake RA: Advances in malignant mesothelioma. N Engl J Med 353: 1591-1603, 2005.
2. Carbone M, Kratzke RA and Testa JR: The pathogenesis of mesothelioma. Semin Oncol 29: 2-17, 2002.
3. Nowak AK, Lake RA, Kindler HL and Robinson BW: New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol 29: 82-96, 2002.
4. Zellos LS and Sugerbaker DJ: Multimodality treatment of diffuse malignant pleural mesothelioma. Semin Oncol 29: 41-50, 2002.
5. Folkman J: Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastasis Rev 9: 171-174, 1990.
6. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT and De Bruijin: Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 56: 549-580, 2004.
7. Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999.
8. Holash J, Wiegand SJ and Yancopoulos GD: New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18: 5356-5362, 1999.
9. WHO. Histological typing of lung cancer and pleural tumours. In collaboration with LH Sobin and pathologists from 14 countries. Travis WD, Colby TV, Corrin C, Shimosato Y and Brambilla E (eds.). Springer, Tokyo, Japan, 1999.
10. Konig JE, Tolnay E, Wiethege T and Muller KM: Expression of vascular endothelial growth factor in diffuse malignant pleural mesothelioma. Virchows Arch 435: 8-12, 1999.
11. Ohta Y, Shridhar V, Kakemkerian GP, Bright RK, Watanabe Y and Pass HI: Thrombospondin-1 expression and clinical implications in malignant pleural mesothelioma. Cancer 85: 2570-2576, 1999.
12. Demirag F, Unsal E, Yilmaz A and Caglar A: Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest 128: 3382-3387, 2005.
13. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
14. Ferrara N: Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 25: 581-611, 2004.
15. Kumar-Singh S, Weyler J, Martin MJ, Vermeulen PB and Van Marck E: Angiogenic cytokines in mesothelioma: A study of VEGF, FGF-1 and -2, and TGFβ expression. J Pathol 189: 72-78, 1999.